Recent Press Releases

Actavis Announces Celebrex® Patent Challenge Settlement

Actavis Announces Celebrex® Patent Challenge Settlement DUBLIN, April 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to...

Lilly Reports First-Quarter 2014 Results

Lilly Reports First-Quarter 2014 Results -- First-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by strong volume...

AstraZeneca First Quarter 2014 financial results

AstraZeneca First Quarter 2014 financial results Revenue up 3% at constant exchange rates (CER) in first quarter. Consolidation of full diabetes franchise contributed 2 percentage points of revenue...

Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio

Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio Net sales of USD 14.0 billion up 1%[1]...

Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet

Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet WHIPPANY, N.J....

Johnson & Johnson to Host Medical Devices & Diagnostics Business Review

NEW BRUNSWICK, N.J., April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of i

Allergan Adopts One-Year Stockholder Rights Plan

Allergan Adopts One-Year Stockholder Rights Plan IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that its Board of...

Groups Urge Vermont Governor To Broaden Zohydro Rules

Groups Urge Vermont Governor To Broaden Zohydro Rules National organizations push for 'more thorough approach' to drug abuse epidemic. WASHINGTON, April 23, 2014 /PRNewswire/ -- Today, the...

BIOGEN IDEC FIRST QUARTER 2014 REVENUES REACH $2.1 BILLION DRIVEN BY CONTINUED STRENGTH OF MS FRANCHISE

BIOGEN IDEC FIRST QUARTER 2014 REVENUES REACH $2.1 BILLION DRIVEN BY CONTINUED STRENGTH OF MS FRANCHISE Wednesday, April 23, 2014 7:00 am EDT Quarter Highlighted by EU Approval of TECFIDERA® and...

Gilead Sciences Announces First Quarter 2014 Financial Results

Gilead Sciences Announces First Quarter 2014 Financial Results - Product Sales of $4.87 billion - - Sovaldi Sales of $2.27 billion - - Non-GAAP EPS of $1.48 per share - - Reiterates Full Year...

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

2014 Revenue and Adjusted EPS Guidance Reaffirmed

THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion 2014 Revenue and Adjusted EPS Guidance Reaffirmed THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN)...

Merck among NASA Cargo Launching to Space Station

Merck among NASA Cargo Launching to Spa​ce Station When the SpaceX-3 cargo resupply mission launched to the International Space Station April 14, an experiment designed by Merck Research Laboratories...

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics Acquires GSK oncology products,...

FDA approves Cyramza for stomach cancer

FDA approves Cyramza for stomach cancer The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction...

GSK announces major 3-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

GSK announces major 3-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders GlaxoSmithKline plc (LSE/NYSE:GSK)...

Lilly Announces Agreement to Acquire Novartis Animal Health

- $5.4 billion deal creates world's second-largest animal health company.

INDIANAPOLIS, April 22, 2014

Lilly's CYRAMZA™ (ramucirumab) Becomes First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the